Jais X, Dartevelle P, Parent F, Sitbon O, Humbert M, Fadel E, Mussot S, Cabrol S, Le Pavec J, Sztrymf B, Tcherakian C, Musset D, Maitre S, Simonneau G
Centre de Référence de l'Hypertension Artérielle Pulmonaire, Unité Propre de Recherche de l'Enseignement Supérieur EA2705, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Clamart, France.
Rev Mal Respir. 2007 Apr;24(4 Pt 1):497-508. doi: 10.1016/s0761-8425(07)91572-7.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease characterized by the persistence of thromboemboli obstructing the pulmonary arteries as an organized tissue. The consequence is an increase in pulmonary vascular resistance resulting in pulmonary hypertension (PH) and progressive right heart failure.
It is difficult to recognize the postembolic nature of PH because there is no known history of thromboembolic disease in more than 50% of cases. Diagnosis is based on the presence of mismatched segmental defects in the ventilation-perfusion scanning. When CTEPH is suspected, pulmonary angiography and high-resolution CT scan are required to establish the diagnosis and to assess the operability. Pulmonary angiography is always performed in conjunction with a diagnostic right heart catheterization, which is required to confirm the diagnosis of PH and to determine the degree of hemodynamic impairement. If there is a good correlation between the pulmonary vascular resistance and the anatomical obstruction, pulmonary endarterectomy (PEA) must be proposed. Otherwise, vasodilator and antiproliferative treatments and lung transplantation represent interesting alternatives.
PEA remains the treatment of choice for eligible patients. Nevertheless, there is a need to conduct randomized trials to assess the efficacy of novel medical therapies in some situations: (1) in inoperable CTEPH due to distal lesions, (2) before PEA (therapeutic bridge) in patients who are considered "high risk" due to extremely poor hemodynamics, (3) in patients with persistent pulmonary hypertension after surgery.
慢性血栓栓塞性肺动脉高压(CTEPH)是一种罕见疾病,其特征是血栓栓子以有组织的形式持续阻塞肺动脉。结果是肺血管阻力增加,导致肺动脉高压(PH)和进行性右心衰竭。
由于超过50%的病例没有已知的血栓栓塞性疾病病史,因此很难识别PH的栓塞后性质。诊断基于通气-灌注扫描中不匹配的节段性缺损。当怀疑患有CTEPH时,需要进行肺血管造影和高分辨率CT扫描以确立诊断并评估手术可行性。肺血管造影总是与诊断性右心导管检查一起进行,这是确认PH诊断并确定血流动力学损害程度所必需的。如果肺血管阻力与解剖学阻塞之间存在良好的相关性,则必须建议进行肺动脉内膜剥脱术(PEA)。否则,血管扩张剂和抗增殖治疗以及肺移植是有趣的替代方案。
PEA仍然是符合条件患者的首选治疗方法。然而,有必要进行随机试验以评估新型药物疗法在某些情况下的疗效:(1)因远端病变而无法进行手术的CTEPH患者;(2)由于血流动力学极差而被认为“高危”的患者在PEA之前(治疗桥梁);(3)手术后持续存在肺动脉高压的患者。